SummitTX Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.53M Buy
10,242
+7,906
+338% +$2.01M 0.07% 301
2026
Q2
$703K Sell
2,336
-1,275
-35% -$385K 0.02% 529
2026
Q1
$1.19M Buy
3,611
+146
+4% +$49.7K 0.04% 404
2025
Q4
$1.38M Sell
3,465
-4,060
-54% -$1.8M 0.04% 360
2025
Q3
$3.43M Buy
7,525
+2,725
+57% +$1.11M 0.14% 165
2025
Q2
$1.57M Sell
4,800
-1,526
-24% -$422K 0.07% 288
2025
Q1
$1.71M Buy
+6,326
New +$1.63M 0.07% 278

Other funds holding ALNY

SummitTX Capital's ALNY Position: Q3 2026 in Review

SummitTX Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 338% in Q3 2026, buying an estimated $2.01M and bringing the position to 10,242 shares worth $2.53M. The position accounts for 0.07% of the portfolio, ranked #301.

SummitTX Capital first reported a position in ALNY in Q1 2025 and has held it in 7 quarters since. The position peaked at $3.43M in Q3 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • SummitTX Capital held 10,242 shares of Alnylam Pharmaceuticals worth $2.53M as of Q3 2026.
  • SummitTX Capital bought 7,906 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $2.01M.
  • Alnylam Pharmaceuticals made up 0.07% of SummitTX Capital's portfolio in Q3 2026, its #301 holding.
  • SummitTX Capital first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • SummitTX Capital's Alnylam Pharmaceuticals position peaked at $3.43M in Q3 2025.
  • 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on SummitTX Capital's 13F filing for Q3 2026, filed 16 Nov 2026.